JAMA Dermatology · 2013 · 22 citations · 10 references
MedicineMolecular GeneticsOncologyCancer GeneticsMolecular OncologyNeoplasiaCancer Genome SequencingCancer GenomicsCancer Molecular PathologyMutation AnalysisNext-generation Sequencing In OncologyReceptor Tyrosine Kinase OncogenesAmino AcidsBraf V600 MutationsBraf V600e MutationCancer Mutation AnalysisMajor Pathologic ResponseMetastatic Melanoma TreatmentSensitivityTumor Mutation Analysis
IMPORTANCE: There is an increasing interest in BRAF V600 mutations in melanomas and their associated sensitivity to vemurafenib, a BRAF inhibitor. However, physicians cannot find information in the literature about vemurafenib response for rare and/or atypical BRAF mutations. OBSERVATIONS: We describe the identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma. Using a pyrosequencing method, we determined that the tumor positive for mutated BRAF, uncovering a novel c.1799_1803delinsAT; p.V600-K601>D variant. We uncovered this atypical BRAF mutation with 2 different sequencing methods, both in the primary lesion and in 1 metastasis. The patient was immediately treated with vemurafenib as monotherapy and achieved a prolonged (5.5-month) positive response. CONCLUSIONS AND RELEVANCE: We analyzed the consequences of the BRAF V600-K601>D mutation in terms of amino acids. We referred to the published data and databases to screen chemical properties of well-known BRAF V600 mutations and other complex BRAF mutations to find common features of activated BRAF mutations. Importantly, we highlighted that both the site of the mutation and the involved amino acids are important to predict vemurafenib response. Our conclusion is that complex BRAF mutation surrounding codon 600 could also be sensitive to BRAF inhibitors.
10
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong et al. · Journal of Clinical Oncology · 2009 · 4.6K citations · Full text
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Paul Wan, Mathew J. Garnett, S. Mark Roe et al. · Cell · 2004 · 2.8K citations · Full text
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Simon Forbes, Nidhi Bindal, Sally Bamford et al. · Nucleic Acids Research · 2010 · 2.3K citations · Full text
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag, Peter Hirth, James Tsai et al. · Nature · 2010 · 1.8K citations
Medicine, Oncology, Pharmacology +14